India, Sept. 8 -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company, announced Tuesday that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026.
Civik has served as Interim Chief Executive Officer since February 2026 and as a member of Pyxis Oncology's Board of Directors since 2021.
In connection with Civik's appointment as Chairman, John Flavin, co-founder and founding Chairman of Pyxis Oncology, will transition to Lead Independent Director and will continue to serve as a member of the Board.
Flavin has provided leadership to Pyxis Oncology since its founding and has played an instrumental role in the Company's formation, growth and evolution into ...